Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis

Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA mutations and impairs SARS-CoV-2 replication in animal models and in humans. Here, we establish the molecular mech...

Descripción completa

Detalles Bibliográficos
Autores principales: Kabinger, Florian, Stiller, Carina, Schmitzová, Jana, Dienemann, Christian, Kokic, Goran, Hillen, Hauke S., Höbartner, Claudia, Cramer, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437801/
https://www.ncbi.nlm.nih.gov/pubmed/34381216
http://dx.doi.org/10.1038/s41594-021-00651-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437801/
https://www.ncbi.nlm.nih.gov/pubmed/34381216
http://dx.doi.org/10.1038/s41594-021-00651-0

Ejemplares similares